Fanconi syndrome in a patient receiving pre-exposure prophylaxis for HIV infection: case report

被引:1
作者
Drak, Douglas [1 ,2 ]
Lin, Jasper [3 ]
Gowers, Andrew [4 ]
Gracey, David M. [2 ,3 ,4 ]
机构
[1] Royal North Shore Hosp, St Leonards, NSW, Australia
[2] Univ Sydney, Fac Med, Cent Clin Sch, Sydney, NSW, Australia
[3] Royal Prince Alfred Hosp, Renal Unit, Camperdown, NSW, Australia
[4] Holdsworth House Med Practice, Coll St, Sydney, NSW, Australia
关键词
emtricitabine; estimated glomerular filtration rate; Fanconi syndrome; HIV prevention; pre-exposure prophylaxis; PrEP; risk reduction; tenofovir disoproxil; TENOFOVIR DISOPROXIL FUMARATE; VIROLOGICALLY SUPPRESSED ADULTS; DOUBLE-BLIND; EMTRICITABINE; ALAFENAMIDE; PHASE-3; DECLINE; REVERSIBILITY; MULTICENTER; ADHERENCE;
D O I
10.1071/SH21185
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. Tenofovir disoproxil is efficacious in the preventing HIV infection as part of a pre-exposure prophylaxis (PrEP) regimen. Although its use has been associated with impaired renal function, instances of Fanconi syndrome are extremely rare. This may change with increased uptake of PrEP. Methods. A 55-year-old male patient (he/him/his) was commenced on PrEP with a baseline estimated glomerular filtration rate (eGFR) of approximately 60 mL/min/1.73 m(2). Results. Within 6 months, he developed new and worsening proteinuria, glycosuria and aminoaciduria despite no apparent change in eGFR. PrEP was discontinued and his urinary abnormalities rapidly resolved. The patient remains off PrEP. Conclusions. Fanconi syndrome is a rare, but known complication of tenofovir disoproxil. This is the first report related to PrEP in Australia. While tenofovir associated nephrotoxicity in patients taking PrEP is uncommon, the patient's age and pre-existing renal impairment placed him at substantially higher risk. At-risk patients need more frequent monitoring of their eGFR and proteinuria. Urinary protein to creatinine ratio is the preferred to dipstick testing for proteinuria and the latter does not readily detect the low molecular wight proteinuria characteristic of tenofovir toxicity. Early recognition of these patients is essential, as prompt cessation of PrEP can often reverse renal abnormalities.
引用
收藏
页码:224 / 227
页数:4
相关论文
共 20 条
[1]   Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients [J].
Ando, Minoru ;
Yanagisawa, Naoki ;
Ajisawa, Atsushi ;
Tsuchiya, Ken ;
Nitta, Kosaku .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (12) :3923-3929
[2]  
Australasian Sexual and Reproductive Health Alliance and Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine, 2021, AUSTR STI MAN GUID U
[3]   Renal impairment in a large-scale HIV preexposure prophylaxis implementation cohort [J].
Drak, Douglas ;
Mcmanus, Hamish ;
Vickers, Tobias ;
Heron, Jack E. ;
Vaccher, Stefanie ;
Zablotska, Iryna ;
Guy, Rebecca ;
Bavinton, Benjamin ;
Jin, Fengyi ;
Grulich, Andrew E. ;
Bloch, Mark ;
O'Connor, Catherine C. ;
Gracey, David M. .
AIDS, 2021, 35 (14) :2319-2326
[4]   Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial [J].
Gallant, Joel E. ;
Daar, Eric S. ;
Raffi, Francois ;
Brinson, Cynthia ;
Ruane, Peter ;
DeJesus, Edwin ;
Johnson, Margaret ;
Clumeck, Nathan ;
Osiyemi, Olayemi ;
Ward, Doug ;
Morales-Ramirez, Javier ;
Yan, Mingjin ;
Abram, Michael E. ;
Plummer, Andrew ;
Cheng, Andrew K. ;
Rhee, Martin S. .
LANCET HIV, 2016, 3 (04) :E158-E165
[5]  
Gandhi M, 2017, AIDS, V31, P2245, DOI [10.1097/QAD.0000000000001615, 10.1097/qad.0000000000001615]
[6]   Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study [J].
Gandhi, Monica ;
Glidden, David V. ;
Mayer, Kenneth ;
Schechter, Mauro ;
Buchbinder, Susan ;
Grinsztejn, Beatriz ;
Hosek, Sybil ;
Casapia, Martin ;
Guanira, Juan ;
Bekker, Linda-Gail ;
Louie, Alexander ;
Horng, Howard ;
Benet, Leslie Z. ;
Liu, Albert ;
Grant, Robert M. .
LANCET HIV, 2016, 3 (11) :E521-E528
[7]  
Grigsby IF, 2010, THER CLIN RISK MANAG, V6, P41
[8]   Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study [J].
Grulich, Andrew E. ;
Guy, Rebecca ;
Amin, Janaki ;
Jin, Fengyi ;
Selvey, Christine ;
Holden, Jo ;
Schmidt, Heather-Marie A. ;
Zablotska, Iryna ;
Price, Karen ;
Whittaker, Bill ;
Chant, Kerry ;
Cooper, Craig ;
McGill, Scott ;
Telfer, Barbara ;
Yeung, Barbara ;
Levitt, Gesalit ;
Ogilvie, Erin E. ;
Dharan, Nila J. ;
Hammoud, Mohamed A. ;
Vaccher, Stefanie ;
Watchirs-Smith, Lucy ;
McNulty, Anna ;
Smith, David J. ;
Allen, Debra M. ;
Baker, David ;
Bloch, Mark ;
Bopage, Rohan I. ;
Brown, Katherine ;
Carr, Andrew ;
Carmody, Christopher J. ;
Collins, Kym L. ;
Finlayson, Robert ;
Foster, Rosalind ;
Jackson, Eva Y. ;
Lewis, David A. ;
Lusk, Josephine ;
O'Connor, Catherine C. ;
Ryder, Nathan ;
Vlahakis, Emanuel ;
Read, Phillip ;
Cooper, David A. .
LANCET HIV, 2018, 5 (11) :E629-E637
[9]   Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence [J].
Hall, Andrew M. ;
Hendry, Bruce M. ;
Nitsch, Dorothea ;
Connolly, John O. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (05) :773-780
[10]   Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure [J].
Jose, Sophie ;
Hamzah, Lisa ;
Campbell, Lucy J. ;
Hill, Teresa ;
Fisher, Martin ;
Leen, Clifford ;
Gilson, Richard ;
Walsh, John ;
Nelson, Mark ;
Hay, Phillip ;
Johnson, Margaret ;
Chadwick, David ;
Nitsch, Dorothea ;
Jones, Rachael ;
Sabin, Caroline A. ;
Post, Frank A. .
JOURNAL OF INFECTIOUS DISEASES, 2014, 210 (03) :363-373